Updated:
BridgeBio Inc.
BridgeBio Inc. invests in biotech and healthcare, operating from five offices in the US and UK with no publicly disclosed principals.
BridgeBio Inc.
BridgeBio Inc. was established with an investment mandate centered on biotechnology and pharmaceutical innovation, though its founding year and principals have not been publicly detailed. The firm's name echoes the well-known publicly traded biotech company BridgeBio Pharma, but the two entities are distinct, and no direct affiliation has been confirmed. The firm allocates capital across biotech startups, clinical-stage therapeutics, and healthcare services, focusing on early- to mid-stage opportunities. Its geographic spread—London, Boca Raton, Palo Alto, New York, and Boston—covers key biotech hubs in the US and Europe. No specific portfolio companies or co-investors have been publicly identified. Total AUM and team size remain undisclosed. The firm's multiple offices suggest a lean team operating across time zones to source deals. No adjacent philanthropic or operating vehicles have been identified in public sources. BridgeBio Inc.'s structural differentiator is its international biotech focus combined with a multi-hub operational model, a configuration uncommon among pure healthcare asset managers. The lack of public information on leadership or strategy limits further assessment.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Additional offices
Boca Raton · Palo Alto · New York · Boston
Sector focus
Frequently asked questions
Who runs investment decisions at BridgeBio Inc.?
BridgeBio Inc. has not publicly named its investment decision-makers, making it unclear who holds roles such as CEO or CIO. The firm's leadership structure is opaque, and no public filings or press releases have identified key individuals.
How does BridgeBio Inc. source proprietary deal flow?
The firm's office locations in London, Palo Alto, Boston, New York, and Boca Raton place it near major biotech clusters, suggesting a reliance on local networks and scientific conferences. However, no specific sourcing methodology has been disclosed.
Is BridgeBio Inc. related to BridgeBio Pharma?
BridgeBio Inc. shares a name with the Nasdaq-listed BridgeBio Pharma, but there is no public evidence of a direct structural or ownership link. The two entities appear distinct, and BridgeBio Inc. does not mention any affiliation in available sources.
What investment stages does BridgeBio Inc. typically target?
BridgeBio Inc. likely targets early- to mid-stage biotech and pharmaceutical opportunities, given its name and sector focus. No specific stage preferences have been confirmed through public documents.
Does BridgeBio Inc. participate in fund commitments or only direct deals?
The firm's investment approach is not publicly defined, but its name suggests direct deal-making in biotech assets rather than fund-of-funds activity. No evidence of fund commitments exists.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: